GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

This study is testing a combination of two drugs — gemcitabine/oxaliplatin chemotherapy plus a targeted therapy and immunotherapy — given before surgery in patients with a type of bile duct cancer inside the liver (intrahepatic cholangiocarcinoma, or ICC) that can be removed but has high-risk features for coming back. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with intrahepatic cholangiocarcinoma (a liver/bile duct cancer) - You have not received any prior cancer treatment - Your tumor is large (over 5 cm), multiple, involves blood vessels, or has features suggesting it may spread - Your liver function and blood counts are adequate - Your cancer is removable by surgery **You may NOT be eligible if:** - You have previously received chemotherapy, immunotherapy, or targeted therapy for this cancer - Your liver function is poor (Child-Pugh class B or C) - Your organs are not healthy enough to tolerate surgery and chemotherapy Talk to your doctor to see if this trial is right for you.